[Gastroduodenal tolerance and clinical effectiveness of therapy with lonazolac-calcium in rheumatic diseases].
Most undesired side effects in therapy with non-steroidal antiinflammatory drugs (NSAID) mainly effect the gastric and duodenal mucosa. The radioimmunological determination of pepsinogen A and C (pepsinogen group I and II) is qualified for inclusion of the functional and morphologic state of the gastroduodenal mucosa. By determination of the pepsinogens group A and C the influence and the gastroduodenal compatibility of the non-steroidal antiinflammatory drug lonazolac Ca (LCa) [Irritren] were examined in a dosage of 600 mg/d during a 2-weeks therapy. 31 patients with various painful rheumatic diseases and 10 healthy probands as a control group were examined. The results show that the treatment with LCa did not significantly effect mean and median of pepsinogen A- and -C levels in serum. Only in 3.7% of the cases a contemporary increase of pepsinogen A and C occurred, which could be estimated as a beginning superficial gastritis. In addition the beneficial clinical efficacy of LCa was documented by a significant decrease of a tripartite pain score from 2.1 to 1.4. The results point to a very good proportion of clinical efficacy and gastroduodenal side-effects of LCa.
Kullich
W
W
Ludwig-Boltzmann-Institut für Rehabilitation interner Erkrankungen, Saalfelden.
Fromme
K
K
Klein
G
G
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004386:Duodenum / Q000187:drug effects*; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects*; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000097:blood / Q000188:drug therapy*; D010147:Pain Measurement; D010435:Pepsinogens / Q000097:blood; D011111:Polymyalgia Rheumatica / Q000097:blood / Q000188:drug therapy*; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects*; D011863:Radioimmunoassay; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010435:Pepsinogens; D011720:Pyrazoles; C017472:lonazolac
Gastroduodenale Verträglichkeit und klinische Wirksamkeit der Therapie mit Lonazolac-Calcium bei rheumatischen Erkrankungen.